Here, we demonstrate that ICI can increase Ephx2 expression, implicating a potential mechanism underlying immunotherapy failure and highlighting the need to further investigate sEH inhibitors as a novel adjuvant to improve the anti-tumor efficacy of ICI. Here, EPHX2 is linked to neoplasm.